VIVES is a multi-sector fund that invests in projects with a positive societal impact
ViroVet is a pioneering company dedicated to the development of innovative and disruptive technologies for the control of viral diseases in livestock. It develops antiviral drugs for complex...
Axinesis is a spin-off of the Université catholique de Louvain (Belgium), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies...
Emolytics is a spin-off company of UCLouvain (Belgium) which is closely supported by the Louvain Technology Transfer Office. The technology originated in the University's research center in 2009 as a...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Willem de Vos, Professor at University of Wageningen ; Patrice Cani, Professor at UCLouvain ; Jean-Christophe Malrieu, CEO A-Mansia :
"As founders and CEO of A-mansia Biotech we experienced essential...
Louvain-la-Neuve, 22 October 2021 – VOCSens raises €2.5 million in seed funding in order to industrialise its gas microsensors. The objective? The aim is to commercialise its micro gas sensors in the
Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the
European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.
Excellent news for people at risk of